Carnavale Resources Ltd (ASX:CAV, FRA:YBB) has cleared a key regulatory hurdle at its Kookynie Gold Project in Western Australia, with the granting of a mining lease that covers all existing project resources and supports the company’s push towards a bankable feasibility study (BFS) and near-term development.
The ASX-listed explorer said Mining Lease M40/362 — which hosts the Swiftsure and Tiptoe high-grade gold resources — has now been formally granted. The project is located around 60 kilometres south of Leonora and 180 kilometres north of Kalgoorlie, within a well-established gold mining region.
Namibia survey to enhance prospect mapping on PEL 93 ahead of future drilling campaign
88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ), an oil and gas exploration company listed in London and Sydney, has said that recent exploration success in Namibia's Damara Fold Belt has strengthened the case for its planned airborne geophysical survey on Petroleum Exploration Licence 93.
Wellnex Life Ltd (ASX:WNX, AIM:WNX) has entered early-stage due diligence following unsolicited approaches for the potential acquisition of its Pain Away brand and other assets, as the health and wellness group explores a range of financing options to support its turnaround strategy.
The company said it had also received an indicative proposal from a syndicate offering convertible note funding to expand the Pain Away brand into Asian and North American markets, in line with its goal of achieving positive free cash flow and long-term profitability.
The collapse of Healthscope has been years in the making, shaped by aggressive financial structuring rather than any sudden failure in patient care.
Once one of Australia’s largest private hospital operators, Healthscope was taken private in 2019 by Brookfield Asset Management in a deal that loaded the business with substantial debt while separating hospital operations from the real estate they sit on. Rent payments to property landlords became a fixed and rising cost, even as private hospital margins came under pressure from labour shortages, rising costs and disputes with health insurers.
Xstate Resources Limited (ASX:XST, FRA:XW7) has upgraded its view of reservoir quality at the Diona gas project in Queensland’s Surat–Bowen Basin, ahead of a staged stimulation and testing program at the Xstate-operated joint venture with Elixir Energy Ltd (ASX:EXR, OTC:ELXPF).
The reassessment follows post-drilling analysis of cuttings from the Diona-1 well, which was cased and suspended in late 2025. Since then, the joint venture has focused on technical studies and operational preparation aimed at de-risking the upcoming testing campaign.
Western Yilgarn NL (ASX:WYX, OTC:WYGXF) has flagged a new high-grade gallium–tellurium target at its Ida Holmes Junction Project in WA’s Northern Goldfields after rock-chip sampling returned standout surface assays across two widely spaced exploration licences.
The early-stage discovery includes gallium grades of up to 185.5 parts per million (ppm) alongside elevated tellurium values. Western Yilgarn said the mineralisation has now been confirmed across Exploration Licences E36/1020 and E36/1046, which are about 39 kilometres apart, suggesting the potential for a large, regionally extensive system rather than isolated occurrences.
China’s SANY International Development and a group of unnamed South Korean companies have signed a deal to support feasibility studies for the proposed Western Green Energy Hub in south-east Western Australia.
Project developer Western Green Energy Hub said the agreement will fund early design work ahead of a final investment decision targeted for 2029.
Golden Dragon Mining Ltd has reported shallow, high-grade gold intersections from its first phase of RC drilling at Coodardy within the broader Cue Gold Project in WA’s Murchison, with results supporting continuity of a high-grade zone inside a wider mineralised system.
Standout intercepts included 8 metres at 7.3 grams per tonne (g/t) Au from 20 metres in 25CD001 (within 24 metres at 2.7 g/t Au), 4 metres at 4.6 g/t Au from 16 metres in 25CD004 (within 16 metres at 1.7 g/t Au), and 4 metres at 9.7 g/t Au from 24 metres in 25CD011 (within 8 metres at 5.1 g/t Au).
Pepper Money (ASX:PPM) has surged 25% in morning trade after confirming it has received a confidential, non-binding and conditional proposal from Challenger Ltd (ASX:CGF) to acquire 100% of the lender via a scheme of arrangement at $2.60 per share.
At midday, shares had come back slightly to be up 23.3% on the day to $2.17.
Fortuna Metals Limited (ASX: FUN) has reported shallow hand-auger drilling results that it says confirm high-grade rutile mineralisation at its Mkanda rutile and graphite project in Malawi.
Assays from 96 hand-auger holes, based on 0–2 metre composites, returned in-situ rutile grades of up to 1.78%, with 36 of the 96 results (37.5%) grading above 1.0% rutile and more than 20% above 1.2%, according to the company.
Critical Resources Ltd (ASX:CRR, FRA:9S70) has outlined a growing multi-commodity discovery pipeline at its Halls Peak project in northern New South Wales, pointing to emerging gold–antimony–silver potential at the Amoco prospect, exceptionally high-grade silver at Gibsons, and progressing land access at the Mayview antimony prospect.
The update follows completed petrographic analysis of maiden drill samples from Amoco, which the company says confirms the presence of a large, structurally controlled orogenic gold–antimony–silver system overprinting earlier volcanic-hosted massive sulphide (VHMS) mineralisation.
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) last week outlined progress on its lead oncology asset HMBD-002, positioning the immunotherapy program to move into Phase II clinical testing following the completion of Phase I studies.
Chief executive officer Dr James Garner said the company had undergone a significant reset, both in terms of its asset base and internal structure, describing HMBD-002 as a completely new opportunity for Percheron Therapeutics Ltd. He noted that the drug had no scientific relationship to previous programs and targets a different disease pathway, making it uncorrelated with earlier setbacks.